Advertisement
UK markets close in 5 hours 21 minutes
  • FTSE 100

    8,048.11
    +24.24 (+0.30%)
     
  • FTSE 250

    19,695.89
    +96.50 (+0.49%)
     
  • AIM

    752.21
    +3.03 (+0.40%)
     
  • GBP/EUR

    1.1595
    +0.0006 (+0.05%)
     
  • GBP/USD

    1.2363
    +0.0012 (+0.10%)
     
  • Bitcoin GBP

    53,532.34
    +197.55 (+0.37%)
     
  • CMC Crypto 200

    1,420.06
    +5.30 (+0.37%)
     
  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     
  • DOW

    38,239.98
    +253.58 (+0.67%)
     
  • CRUDE OIL

    82.00
    +0.10 (+0.12%)
     
  • GOLD FUTURES

    2,309.40
    -37.00 (-1.58%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     
  • DAX

    17,990.66
    +129.86 (+0.73%)
     
  • CAC 40

    8,068.86
    +28.50 (+0.35%)
     

Exploring JNJ’s Key Oncology Assets in the First Quarter

Exploring JNJ’s Key Oncology Assets in the First Quarter

Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)Imbruvica’s trendsIn the first quarter, Johnson & Johnson (JNJ) and AbbVie’s (ABBV) Imbruvica reported 40% YoY (year-over-year) growth in